Monoclonal antibodies

Monoclonal antibodies
#GLP-1 #Monoclonal antibodies #Obesity #Phase II trial #Skye Bioscience #Weight loss

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More

#Editor's Choice #News

Gastric cancer
#Astellas Pharma #Gene mutation #MHRA #Monoclonal antibodies #Oncology

First claudin 18.2 biomarker targeted therapy licensed in Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Astellas’ Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody. It is licensed in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric… Read More

#News #Regulatory

#CatalYm #Financing #Monoclonal antibodies #Oncology #Phase II trial

CatalYm raises $150m for cancer therapy visugromab

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon… Read More

#Business & Investment #Cancer Research #News

Monoclonal antibody
#Autoimmune disease #Janssen #Monoclonal antibodies #Neurology #Phase III trial

Janssen reports positive data for myasthenia gravis treatment

Janssen-Cilag has reported positive results from its Phase III Vivacity-MG3 study assessing its nipocalimab therapy for the treatment of patients with generalised myasthenia gravis (gMG). The Johnson & Johnson company showcased the data in a presentation at the European Academy of Neurology (EAN) 2024 Congress and… Read More

#News

Enterovirus
#Clinical trial #Monoclonal antibodies #National Institutes of Health (NIH) #Virology

Trial to test monoclonal antibody for virus of growing concern

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). AFM has emerged in the United States… Read More

#News #Trending News

Immune thrombocytopenia test
#Events #ITP #Monoclonal antibodies #Phase II trial #Takeda

Favourable results for mAb in bleeding disorder shared at ISTH

Takeda has shared positive results from its Phase IIb study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterised by the accelerated destruction of platelets in blood, resulting… Read More

#News

Human cells
#Cytomos #Immunotherapy #iPSC #Monoclonal antibodies #Single-cell analysis

Cytomos launches new benchtop cell analyser

TechBio Cytomos has launched a new benchtop cell analyser called Celledonia, which uses the company’s AuraCyt platform. Celledonia has been designed to provide cell-specific insights for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs). The new technology could… Read More

#News

Molecular,Model,Of,Antibody
#Drug discovery #Monoclonal antibodies #Therapeutic Antibodies #Webinar

Where is the opportunity in the therapeutic antibody market?

In this webinar, you will hear from Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader – Scientific Solutions Consulting at Benchling, and Dr… Read More

Webinar date:
Brought to you by Benchling & Bio-Rad
#Webinars

Monoclonal antibody
#Bioprocessing #Drug discovery #Monoclonal antibodies #Sustainability

How single-use technologies can improve antibodies production  

DDW Editor Reece Armstrong speaks to David Chau, Global Bioprocess Application Specialist, Purification and Filtration Business, Solventum, formerly 3M Health Care, about challenges in producing monoclonal antibodies (mAbs) and how single-use technologies can simplify processes.   RA: What are some of the current limitations for producing mAbs? DC: For the… Read More

#Exclusive Content

Child receiving treatment for malaria
#Africa #Clinical trial #Malaria #Monoclonal antibodies #Therapeutic Antibodies

Experimental malaria monoclonal antibody prevents infection

A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. L9LS binds to and neutralises ‘sporozoites’, the form of the malaria parasite transmitted by mosquitoes that… Read More

#News #Trending News

#Antibodies #Artificial intelligence (AI) #Monoclonal antibodies #Therapeutic Antibodies

Therapeutic antibody potential in 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab)1. This won't come as a surprise when you look at industry milestones… Read More

#Exclusive Content

Monoclonal antibody
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

eBook: Drug discovery and the impact of mAbs

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as… Read More

#News

Monoclonal antibodies eBook cover
#Antibodies #Drug discovery #eBook #Monoclonal antibodies #Therapeutic Antibodies

Drug discovery and the impact of mAbs

This eBook, sponsored by Thermo Fisher Scientific, explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future. Download this exclusive eBook to… Read More

#DDW eBooks #Intelligence

Human antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Opportunity in the antibody market: Hear from the experts

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Monoclonal antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: How can we develop better therapeutic antibodies?

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News

Antibodies
#Antibodies #Antibody discovery workflow #Antibody-based therapeutics #Monoclonal antibodies #Therapeutic Antibodies

Webinar: Innovations and opportunities in the therapeutic antibody market

Join DDW for this free event ‘Where is the opportunity in the therapeutic antibody market?’, which is co-sponsored by Bio-Rad and Benchling. The event will take place on 30 April at 3PM BST / 4pm CEST / 10am EDT / 7am PDT. Read More

Webinar date:
Co-sponsored by Benching and Bio-Rad
#News